Bo Ying
Chief Executive Officer Abogen Biosciences
Dr. Bo Ying has over a decade of experience in nucleic acid-based therapeutics and drug development. He founded Abogen, a biotechnology company focused on curing untreatable diseases using mRNA technology. Under his leadership, Abogen developed a proprietary mRNA platform that led to the approval of China’s first mRNA COVID-19 vaccine. Prior to this, Dr. Ying held various roles in leading biopharmaceutical companies, specializing in drug formulation and manufacturing. He earned a bachelor’s from Fudan University and a Ph.D. from Northeastern University. He has authored numerous patents and published in top journals, and served as president of the Chinese-American BioMedical Association.
Seminars
Tuesday 7th April 2026
Fireside Chat: Bridging In Vitro/In Vivo Translation by Overcoming Limitations of Potency Assays & Animal Models to Accelerate Clinic Progress
2:30 pm
- What key factors should guide the selection of cell lines to develop bioassays that best predict in vivo LNP potency?
- How to design quantitative assays that measure relevant payload expression levels for understanding biological activity?
- Which animal models provide the most reliable assessment of LNP potency and how to better address variability in biodistribution and protein corona formation between species?
Tuesday 7th April 2026
An ‘Irrational’ Ionizable Lipid Design Approach Based on Machine Learning Models
3:30 pm
- Conventional ionizable lipid design approach is based on SAR model, innovative ionizable lipid structures are limited, SM-102 and Lipid-5 are still the benchmark for mRNA delivery
- Abogen has established a library of ionizable lipids with in vivo test results to train our in-house machine learning model and as the model matures, we have gradually switched from rational design to AI-driven ionizable lipid generation approach
- The AI-driven lipid generator has created some truly innovative structures that demonstrated superior properties not only in efficiency and safety, it may help to overcome some intrinsic limitations in LNPs during repeated i.v. dosing
NEW DATA
